Northwest Biotherapeutics, Inc. | 10-Q: FY2025 Q1 Revenue: USD 375 K

Revenue: As of FY2025 Q1, the actual value is USD 375 K.

EPS: As of FY2025 Q1, the actual value is USD -0.01.

Segment Revenue

• Research and Other Revenue: $375,000 for the three months ended March 31, 2025, compared to $284,000 for the same period in 2024.

Operational Metrics

• Net Loss: The company reported a net loss of $19.3 million for the three months ended March 31, 2025, compared to $18.3 million for the same period in 2024.
• Research and Development Expenses: $8.4 million for the three months ended March 31, 2025, compared to $7.9 million for the same period in 2024.
• General and Administrative Expenses: $9.3 million for the three months ended March 31, 2025, compared to $8.1 million for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $9.4 million for the three months ended March 31, 2025, compared to - $12.4 million for the same period in 2024.
• Net Cash Used in Investing Activities: - $93,000 for the three months ended March 31, 2025, compared to - $239,000 for the same period in 2024.
• Net Cash Provided by Financing Activities: $11.7 million for the three months ended March 31, 2025, compared to $12.1 million for the same period in 2024.

Unique Metrics

• Convertible Notes at Fair Value: $35.9 million as of March 31, 2025, compared to $34.2 million as of December 31, 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue its progress on multiple fronts, including the MAA application process, manufacturing scale-up in the Sawston, UK facility, and preparations for clinical trials of DCVax-Direct.
• Non-Core Business: The company is expanding its compassionate use programs and pursuing litigation against certain market makers.
• Priority: The company is focused on submitting initial INDs for clinical trials of DCVax-Direct during Q2 of this year and expanding its manufacturing capabilities.